Gwent man starts YouTube channel on his experience living with incurable condition
MS or as it's medically known Multiple sclerosis is a chronic, often disabling, disease that affects the brain and spinal cord.
It's an autoimmune condition where the body's immune system mistakenly attacks the protective myelin sheath that covers nerve fibres.
In some cases, MS can lead to paralysis, speech difficulties, and bladder or bowel problems.
There is no cure for MS however, treatments can slow its progression.
Mike Gale runs a You Tube account called Myelin and Me focused around MS (Image: Mike Gale) Mike Gale, 49, from Newport and now living in Cwmbran, has been making videos on his Youtube Channel 'Myelin and Me.'
Mike was officially diagnosed with MS in 2019 after years of unexplained symptoms and has grossed around 100 subscribers through his platform.
Mike said: 'One of the reasons I'm doing the channel is because I think, had I known more at the time, I could have been diagnosed earlier.
'I was left to manage things on my own. Cramps, tremors, and everything else. I started off okay but then it progressed quite rapidly, which was a bit of a bind really.'
Mike Gale runs a You Tube account called Myelin and Me focused around MS (Image: Mike Gale) Mike's journey began in 2015 whilst out on a run, he told the Argus: 'My left leg started hitting the floor oddly.'
After this he was diagnosed with a variety of conditions, but none explained what was really going on.
It wasn't until 2018, after Mike and his wife took matters into their own hands that things started moving.
He said: 'Eventually I had scans that showed lesions on my brain and spine, and a lumbar puncture confirmed that I had MS.'
Unfortunately for Mike, his MS had progressed to non-active secondary progressive MS which meant that disease-modifying therapies (DMTs) were no longer an option for him.
He now uses a wheelchair.
Mike Gale runs a You Tube account called Myelin and Me focused around MS (Image: Mike Gale) Despite the setbacks, Mike is determined to make a difference and Myelin and Me is a raw, unfiltered look at life with MS.
Mike said: 'There wasn't anything out there that really showed what MS looks like day to day. It's not polished or perfect it's real.
'I wanted to raise awareness, bust some myths, and help people with MS feel seen and less alone.'
Some of the videos on Myelin and Me includes 'Alcohol made my MS worse, and I didn't even realise it' and 'Ms & PIP How to survive the Pip assessment.'
Mike Gale runs a You Tube account called Myelin and Me focused around MS (Image: NQ) In addition to running his channel, Mike works full-time and credits his employer for being incredibly supportive, allowing him to work from home and he's not stopping there.
On September 27, Mike will be taking on a major challenge. Climbing Pen y Fan. The goal is to prove people with MS can still live a fulfilling life.
Mike explained: 'A friend of mine who also has MS called me and said, 'I'm building a wheelchair to get up Pen y Fan and I'm building one for you too.'
Mike of course said yes. He said: 'No matter how bad your condition is, you can still do stuff.'
Mike's channel can be viewed here alongside his website which also raises awareness surrounding MS.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
7 hours ago
- Miami Herald
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today proudly announced the appointment of Nancy Davis, a globally recognized philanthropist, tenacious advocate, and the visionary founder of the renowned Race to Erase MS and Cure Addiction Now foundations, to its Board of Directors. Ms. Davis brings an unparalleled fusion of deep-seated patient advocacy, strategic fundraising, and a profound, personal commitment to accelerating scientific discovery in areas of critical unmet medical need. Her decades of consummate resilience and unwavering patient-centric approach, born from personal experience, make her an ideal and impactful addition to the Board. Ms. Davis's formidable journey into medical advocacy was ignited by her own diagnosis of multiple sclerosis (MS) in 1991, at the age of 33. Despite being told there was little hope, Nancy refused to accept this prognosis, proactively seeking new therapies and embracing a health-conscious lifestyle. This deeply personal challenge fueled her determination to fundamentally transform the landscape of MS research and treatment. In 1993, she established the Race to Erase MS, an organization that has since raised over $56 million, directly catalyzing groundbreaking research through its innovative "Center Without Walls" program. This pioneering initiative actively dismantles traditional research silos, fostering unprecedented collaboration among leading institutions such as UC San Francisco, Harvard, Yale, USC, Johns Hopkins, UCLA, Cedars-Sinai, and Oregon Health Sciences University. Under her visionary leadership, Race to Erase MS has funded numerous pilot studies instrumental in developing FDA-approved therapies, including the scientific discoveries in B-Cell therapies like Ocrevus®, Briumvi®, and Kesimpta®, which are now gold standards of MS treatment and have completely changed the landscape of the disease. When Nancy founded the organization, there were no FDA-approved treatments for MS but her guiding principle, "take the impossible and make it possible," perfectly encapsulates her profound impact. "Tharimmune is incredibly honored and privileged to welcome Nancy Davis to our Board," said Vincent LoPriore, Executive Chairman of the Board of Director. "Nancy's extraordinary dedication to advancing medical research, coupled with her unique and powerful perspective as both a patient advocate and a formidable force for scientific collaboration, is absolutely invaluable as we continue to develop innovative, life-saving therapies. Her vision aligns perfectly with our mission to bring life-changing solutions to patients, especially as we advance our investigational product, TH104. Our lead is being specifically developed to counter the effects of weaponized fentanyl for military use and chemical incident responders, and it may potentially hold significant promise for broader applications in addressing the devastating opioid crisis. Nancy's profound understanding of patient needs and her unwavering commitment to finding solutions for addiction make her an indispensable and critical voice on our Board. Her proven track record of converting personal adversity into global advocacy and tangible scientific progress is truly inspiring." Ms. Davis co-founded Cure Addiction Now (CAN) with her son, Jason and this pivotal foundation is dedicated to revolutionizing the understanding and treatment of substance use disorder (SUD) by funding cutting-edge, collaborative research that addresses both the physical and emotional aspects of addiction. CAN aims to find therapies that combat withdrawal and cravings, with the ultimate goal of achieving lasting sobriety. Her transformative work with CAN continues to fiercely challenge stigmas and relentlessly push for scientific breakthroughs to combat one of the most pressing public health crises of our time. "I am thrilled and deeply motivated to join the Board of Directors at Tharimmune and contribute to their ongoing, exciting work," said Nancy Davis. "Throughout my career, I've seen firsthand the profound power of focused, collaborative scientific endeavor to bring about real, tangible change for patients. I am deeply impressed by Tharimmune's commitment to developing critical countermeasures, such as TH104. My personal experiences with the devastating impact of addiction have only strengthened my resolve to support truly innovative solutions and I eagerly look forward to contributing my insights and advocacy to help accelerate the development and potential broader impact of this solution and other transformative therapies." About Tharimmune, is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: Forward Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release. Contacts:Tharimmune, SOURCE: Tharimmune Inc.
UPI
a day ago
- UPI
Multiple sclerosis could affect health years before classic symptoms
New research from Canada's University of British Columbia found patients diagnosed with multiple sclerosis started to experience new health issues up to 15 years before showing the classic symptoms of the condition. Photo by Adobe Stock/HealthDay Aug. 4 (UPI) -- People with multiple sclerosis, or MS, begin experiencing new health issues up to 15 years before the classic signs of the illness appear, Canadian research shows. "MS can be difficult to recognize as many of the earliest signs -- like fatigue, headache, pain and mental health concerns -- can be quite general and easily mistaken for other conditions," study senior author Helen Tremlett noted. "Our findings dramatically shift the timeline for when these early warning signs are thought to begin, potentially opening the door to opportunities for earlier detection and intervention," said Tremlett, a professor of neurology at the University of British Columbia in Vancouver. Her team published its findings Friday in JAMA Network Open. MS is an autoimmune illness in which the body's immune system goes awry, attacking the protective myelin sheath that surrounds nerves within the brain and along the spinal cord. Communication breaks down between the brain and the body, leading to progressive disability. The new study that suggests MS may begin more than a decade before a clinical diagnosis. Tremlett's group combed through British Columbia health data for 12,000 people with or without MS. Records went back as far as 25 years prior to an MS patient's diagnosis. That's far longer than the five to 10 years covered in earlier studies looking at disease onset. The main findings: Fifteen years before the onset of classic MS symptoms, there was a noticeable uptick in patient visits to their general practitioner, or in visits to specialists for issues like fatigue, pain and dizziness, as well as mental health issues such as anxiety and depression. Twelve years before symptom onset, visits to psychiatrists began to rise. Eight to nine years before, visits to neurologists and eye specialists rose, perhaps linked to issues such as blurred vision or eye pain. Three to five years before, researchers noted a rise in visits to emergency departments and/or radiology facilities. One year before, visits peaked for a wide range of different physician types, such as neurologists, radiologists and emergency doctors. "These patterns suggest that MS has a long and complex prodromal phase -- where something is happening beneath the surface but hasn't yet declared itself as MS," said study first author Dr. Marta Ruiz-Algueró, a postdoctoral fellow at UBC. "We're only now starting to understand what these early warning signs are, with mental health-related issues appearing to be among the earliest indicators," she added in a news release. The researchers stressed that the early issues that drove MS patients to seek out care can be caused by a myriad of health conditions. Simply experiencing these conditions does not mean a person will go on to develop MS. Nevertheless, "By identifying these earlier red flags, we may eventually be able to intervene sooner -- whether that's through monitoring, support or preventive strategies," Tremlett said a university news release. "It opens new avenues for research into early biomarkers, lifestyle factors and other potential triggers that may be at play during this previously overlooked phase of the disease." More information Find out more about multiple sclerosis at the National Multiple Sclerosis Society Copyright © 2025 HealthDay. All rights reserved.
Yahoo
2 days ago
- Yahoo
Glyphosate ‘most effective method' for council's weedkilling
Glyphosate-based herbicides continue to be used for weedkilling, Caerphilly County Borough Council has said. The chemical has drawn controversy in recent years amid allegations about possible carcinogenic effects, which continue to be debated and challenged. In July 2020, a Caerphilly Council officer said the local authority would look at 'suitable alternatives' for weed treatments while using glyphosate. Five years on, a council spokesperson said Caerphilly 'continues to use glyphosate-based herbicides, which remain licensed in the UK until at least December 2026, pending further review'. The spokesperson said roadside weedkilling is conducted by a contractor using 'precision spraying technology'. This is 'currently the most effective method for treating weeds on roads and footpaths', and while 'alternatives exist, they have proven less effective at scale'. The council also uses glyphosate for countryside management, 'but only as a last resort to treat invasive species such as Japanese knotweed, himalayan balsam, and giant hogweed', the spokesperson explained. In 'some cases' it is also used in controlled areas for stump treatment or bracken control 'where other options are unavailable'. The spokesperson said the council 'remains committed to minimising chemical use where possible while maintaining safe and accessible public spaces'. The council also pointed to a 2022 weedkiller study run by Cardiff Council which trialled a 'highly-concentrated' vinegar, and a hot foam treatment, as possible alternatives to glyphosate. Following the study, the council said an independent scientific report concluded glyphosate was 'the most effective and sustainable weed control method currently available'. It was also the 'least expensive product tested and ranked highest for customer satisfaction', Cardiff Council said at the time.
